Report Overview

Germanys Cardiovascular therapeutics market size stood at around USD XX.X billion in 2019 and is projected to reach USD xx billion by 2028, exhibiting a CAGR of 1.9% during the forecast period.

Cardiovascular diseases are the leading cause of death in Germany, causing a total of approximately 40% of all deaths. In addition, they are associated with significant health consequences for the individual and result in high medical costs for society.

Due to their prevalence, coronary heart disease, heart attacks, and stroke have particularly high public health relevance.



Market Driving and Restraining Factors

Market Drivers

The market is driven by a host of factors which include a rise in the aging population, a rise in per capita spending on healthcare, and an epidemic of general medical issues like obesity and diabetes.

With cardiovascular disorders being the most common cause for morbidity and mortality, the market has a tremendous value and continues to do so in the coming years.

Restraining Factors

There are a few restraints the market likes to overcome which include rising costs for drug development and lowering of the target population. And, despite high prevalence, drug development pipelines for cardiovascular disorders have been stagnant for a variety of reasons